Celia Lin • UCSF Profiles (original) (raw)

  1. Impact of Scleroderma-Associated Autoantibodies on Clinical Outcome Assessments: Post Hoc Analysis From a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial of Tocilizumab in Scleroderma. ACR Open Rheumatol. 2025 Jan; 7(1):e11782. Al Dulaijan B, Huang S, Lin CJF, Denton CP, Khanna D. PMID: 39846245; PMCID: PMC11755119.
    View in: PubMed Mentions: 1
  2. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024 06; 105(6):1306-1315. Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RKS, Singh H, Tesar V, Lin CJF, Barratt J. PMID: 38552841.
    View in: PubMed Mentions: 47 Fields:
    Translation:HumansCTClinical Trials
  3. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2024 02 01; 63(2):472-481. Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, Zucchetto M, Huang S, Jennings A, Nihtyanova SI, Denton CP. PMID: 37228011; PMCID: PMC10836965.
    View in: PubMed Mentions: 17 Fields:
    Translation:HumansCTClinical Trials
  4. Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis. Clin Immunol. 2023 09; 254:109695. Sheng XR, Gao X, Schiffman C, Jiang J, Ramalingam TR, Lin CJF, Khanna D, Neighbors M. PMID: 37479123.
    View in: PubMed Mentions: 11 Fields:
    Translation:HumansCellsCTClinical Trials
  5. Atacicept-it's not over until the wolf-lady sings (or maybe howls). Rheumatology (Oxford). 2023 04 03; 62(4):1359-1361. Isenberg DA, Lin CJF. PMID: 36087007.
    View in: PubMed Mentions: 1 Fields:
  6. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022 03 15; 205(6):674-684. Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. PMID: 34851799.
    View in: PubMed Mentions: 52 Fields:
    Translation:HumansCTClinical Trials
  7. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022 03 01; 50(3):398-409. Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratalà J, François B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Kheradmand F, Rosas IO, Cai F. PMID: 34612846; PMCID: PMC8855771.
    View in: PubMed Mentions: 22 Fields:
    Translation:HumansCellsCTClinical Trials
  8. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. Open Forum Infect Dis. 2022 Jan; 9(1):ofab608. Kumar PN, Hernández-Sánchez J, Nagel S, Feng Y, Cai F, Rabin J, Morse CG, Nadig NR, Ashraf O, Gotur DB, McComsey GA, Gafoor K, Perin P, Thornton SC, Stubbings W, Lin CJF, Tsai L. PMID: 35024375; PMCID: PMC8690270.
    View in: PubMed Mentions: 11
  9. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021 07; 73(7):1301-1310. Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D, focuSSced Investigators. PMID: 33538094; PMCID: PMC8238790.
    View in: PubMed Mentions: 92 Fields:
    Translation:HumansCTClinical Trials
  10. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Ann Rheum Dis. 2021 05; 80(5):641-650. Khanna D, Huang S, Lin CJF, Spino C. PMID: 33257497; PMCID: PMC10750249.
    View in: PubMed Mentions: 27 Fields:
    Translation:Humans
  11. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 10; 8(10):963-974. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators. PMID: 32866440.
    View in: PubMed Mentions: 292 Fields:
    Translation:HumansCTClinical Trials
  12. Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population. Rheumatol Ther. 2020 Mar; 7(1):89-99. Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K. PMID: 31734871; PMCID: PMC7021840.
    View in: PubMed Mentions: 6
  13. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. Osteoporos Int. 2019 Sep; 30(9):1855-1864. Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A. PMID: 31201481; PMCID: PMC6719332.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCTClinical Trials
  14. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. J Bone Miner Res. 2019 06; 34(6):1033-1040. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, de Greg?rio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM. PMID: 30919997; PMCID: PMC6852155.
    View in: PubMed Mentions: 47 Fields:
    Translation:Humans
  15. Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez. Ann Rheum Dis. 2019 11; 78(11):e124. Khanna D, Jahreis A, Lin CJF. PMID: 30352886.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  16. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting. J Rheumatol. 2018 Feb; 45(2):170-176. Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler L, Balasubramanian A, Pannacciulli N, Lin CJF, Roy-Gayos P, Bensen WG, Bensen R, Adachi JD. PMID: 29142041.
    View in: PubMed Mentions: 13 Fields:
    Translation:Humans
  17. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018 02; 77(2):212-220. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE. PMID: 29066464; PMCID: PMC5867414.
    View in: PubMed Mentions: 100 Fields:
    Translation:HumansCTClinical Trials
  18. Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskelet Disord. 2017 04 27; 18(1):174. Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S. PMID: 28449657; PMCID: PMC5408481.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCTClinical Trials
  19. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016 11; 27(11):3239-3249. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR. PMID: 27273113.
    View in: PubMed Mentions: 43 Fields:
    Translation:Humans
  20. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015 Dec; 26(12):2773-83. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. PMID: 26202488; PMCID: PMC4656716.
    View in: PubMed Mentions: 110 Fields:
    Translation:HumansCTClinical Trials
  21. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. 2011 Oct 23; 12(12):1184-93. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A. PMID: 22019834; PMCID: PMC3419270.
    View in: PubMed Mentions: 143 Fields:
    Translation:HumansAnimalsCells
  22. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A. 2010 Feb 23; 107(8):3505-10. Li L, Fang CJ, Ryan JC, Niemi EC, Lebrón JA, Björkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, Seaman WE. PMID: 20133674; PMCID: PMC2840523.
    View in: PubMed Mentions: 217 Fields:
    Translation:HumansCells
  23. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol. 2009 Sep 01; 183(5):3150-9. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. PMID: 19667083; PMCID: PMC2899487.
    View in: PubMed Mentions: 21 Fields:
    Translation:HumansAnimalsCells
  24. Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine. 2008 Dec 30; 26 Suppl 8:I22-7. Liszewski MK, Fang CJ, Atkinson JP. PMID: 19388160; PMCID: PMC2768381.
    View in: PubMed Mentions: 16 Fields:
    Translation:HumansAnimalsCells
  25. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008 Nov; 143(3):336-48. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. PMID: 18691170.
    View in: PubMed Mentions: 34 Fields:
    Translation:Humans
  26. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008 Jan 15; 111(2):624-32. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. PMID: 17914026; PMCID: PMC2200836.
    View in: PubMed Mentions: 69 Fields:
    Translation:HumansCells
  27. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007 Jan; 44(1-3):111-22. Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. PMID: 16882452.
    View in: PubMed Mentions: 58 Fields:
    Translation:Humans
  28. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006 Aug 15; 108(4):1267-79. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP. PMID: 16621965; PMCID: PMC1895874.
    View in: PubMed Mentions: 289 Fields:
    Translation:HumansCellsCTClinical Trials
  29. Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev. 2005 Nov; 4(8):515-9. La Cava A, Fang CJ, Singh RP, Ebling F, Hahn BH. PMID: 16214088.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansAnimalsCells
  30. The rationale for renewed interest by physicians in nutrition. Curr Atheroscler Rep. 1999 Nov; 1(3):173-5. Pearson TA, Bloch R, Dorantes J, Gordian A, Fang C, Swanson J, Brown K. PMID: 11122707.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  31. The effects of graded hypoxia on intraparenchymal arterioles in rat brain slices. Neuroreport. 1998 May 11; 9(7):1419-23. Staunton M, Dulitz MG, Fang C, Schmeling WT, Kampine JP, Farber NE. PMID: 9631440.
    View in: PubMed Mentions: 3 Fields:
    Translation:Animals
  32. Conformation of T4 lysozyme in solution. Hinge-bending motion and the substrate-induced conformational transition studied by site-directed spin labeling. Biochemistry. 1997 Jan 14; 36(2):307-16. Mchaourab HS, Oh KJ, Fang CJ, Hubbell WL. PMID: 9003182.
    View in: PubMed Mentions: 72 Fields:
    Translation:Cells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs